Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2022 | Lung cancer screening via biomarkers

Luis Montuenga • 28 Mar 2022
ELCC 2022
Lung Cancer

Luis Montuenga, MD, Clinica Universidad de Navarra, Pamplona, Spain, discusses utilizing various molecular biomarkers in screening for lung cancer, including proteins circulating the blood and circulating tumor DNA (ctDNA), which can aid in defining risk levels of patients as low, intermediate, or high-risk. This interview took place during the virtual European Lung Cancer Congress 2022.

More from Luis Montuenga

2:09
The advances and limitations of genetic testing for actionable mutations
Luis Montuenga • 28 Mar 2022
1:59
The development of cell line models for the investigation of metastasis and IO in LUSC
Luis Montuenga • 28 Mar 2022

Related Videos

0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
1:56
Challenges and opportunities in TILs and TCR modified cell therapies
Sebastian Klobuch • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals